An Intuitive Approach for Predicting Potential Human Health Risk with

Aug 15, 2017 - In vitro–in vivo extrapolation (IVIVE) analyses translating high-throughput screening (HTS) data to human relevance have been limited...
2 downloads 10 Views 1MB Size
Subscriber access provided by UNIVERSITY OF ADELAIDE LIBRARIES

Article

An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library Nisha S Sipes, John F. Wambaugh, Robert Pearce, Scott S. Auerbach, Barbara Anne Wetmore, Jui-Hua Hsieh, Andrew J. Shapiro, Daniel Svoboda, Michael J DeVito, and Stephen S. Ferguson Environ. Sci. Technol., Just Accepted Manuscript • DOI: 10.1021/acs.est.7b00650 • Publication Date (Web): 15 Aug 2017 Downloaded from http://pubs.acs.org on August 17, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Environmental Science & Technology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 32

Environmental Science & Technology

1

An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library

2

Nisha S. Sipes1*, John F. Wambaugh2, Robert Pearce2, Scott S. Auerbach1, Barbara A. Wetmore4, Jui-Hua

3

Hsieh1, Andrew J. Shapiro1, Daniel Svoboda3, Michael J. DeVito1, Stephen S. Ferguson1

4

1NTP/NIEHS/NIH, RTP, NC

5

2NCCT/ORD/EPA, RTP, NC

6

3Sciome, RTP, NC

7

4NERL/ORD/EPA, RTP, NC

8

*Corresponding Author: Nisha S. Sipes, 111 T.W. Alexander Drive, PO Box 12233, MD: K2-17, Research

9

Triangle Park, NC 27709, Telephone: 919-316-4603, Email: [email protected]

10 11 12 13 14 15 16 17 18 19 20 21 22 23

ACS Paragon Plus Environment

Environmental Science & Technology

24

ABSTRACT

25

In vitro-in vivo extrapolation (IVIVE) analyses translating high-throughput screening (HTS) data to human

26

relevance have been limited. This study represents the first report applying IVIVE approaches and

27

exposure comparisons using the entirety of the Tox21 federal collaboration chemical screening data,

28

incorporating assay response efficacy and quality of concentration-response fits, and providing

29

quantitative anchoring to first address the likelihood of human in vivo interactions with Tox21

30

compounds. This likelihood was assessed using a maximum blood concentration to in vitro response

31

ratio approach (Cmax/AC50), analogous to decision-making methods for clinical drug-drug interactions.

32

Fraction unbound in plasma (fup) and intrinsic hepatic clearance (CLint) parameters were estimated in

33

silico and incorporated in a 3-compartment toxicokinetic (TK) model to first predict Cmax for in vivo

34

corroboration using therapeutic scenarios. Toward lower exposure scenarios, 36 compounds of 3,925

35

with curated activity in the HTS data using high quality dose-response model fits and ≥40% efficacy gave

36

‘possible’ human in vivo interaction likelihoods lower than median human exposures predicted in EPA’s

37

ExpoCast program. A publicly available web application has been designed to provide all Tox21/ToxCast

38

dose likelihood predictions. Overall, this approach provides an intuitive framework to relate in vitro

39

toxicology data rapidly and quantitatively to exposures using either in vitro or in silico derived TK

40

parameters, and can be thought of as an important step towards estimating plausible biological

41

interactions in a high throughput risk assessment framework.

42 43 44 45 46 47

ACS Paragon Plus Environment

Page 2 of 32

Page 3 of 32

48

Environmental Science & Technology

TOC/Abstract Art

49 50 51

INTRODUCTION

52

Likelihood of an adverse human response to environmental chemical exposure is not adequately

53

characterized for most of the thousands of chemicals with potential human exposure due to the

54

limitations of traditional toxicity testing methods.1 To address the needs for higher throughput

55

approaches reflective of human molecular pathways, the Toxicology in the 21st Century(Tox21) federal

56

collaboration was formed with an initial focus of employing in vitro high-throughput screening (HTS)

57

assays with a 10k chemical library (e.g., environmental, pharmaceutical, consumer- and industrial-use) in

58

>60 HTS assays (e.g., cytotoxicity, cell stress, mitochondrial, nuclear receptors).2 Of these chemicals,

59

>1,000 have been evaluated in the EPA’s ToxCast program (>800 HTS assays) to broaden the biological

60

coverage.3 Hazard-based chemical assessments, using HTS data, have related chemicals to biological

61

pathways responsible for adverse in vivo effects, but have typically not incorporated concentrations or

62

estimated required doses needed to achieve these effects.4-9 While hypothesized pathways of concern

63

are uncovered, doses at which these effects may manifest remain generally unknown and unaddressed

64

for Tox21 data.

65

ACS Paragon Plus Environment

Environmental Science & Technology

66

Recent efforts are building quantitative approaches to translate in vitro toxicity potencies to equivalent

67

in vivo doses using in vitro-in vivo extrapolation (IVIVE) techniques.10-13 These approaches utilize

68

pharmacokinetic equations to estimate chemical steady-state concentrations (Css) in plasma and to

69

dosimetrically adjust in vitro HTS potencies to estimate external dose equivalents (intake rates).10-13

70

Additionally the High-Throughput Toxicokinetic (HTTK) open-source R-package14, 15 can quickly calculate

71

equivalent external doses from HTS data using multiple IVIVE models, and conversely, calculate plasma

72

concentrations given certain dosing scenarios. The current R-package utilizes in silico estimated

73

physicochemical parameters (e.g., hydrophobicity, acid/base dissociation constants) and two widely

74

applied in vitro measured parameters, the chemical fraction unbound in plasma (fup) and the intrinsic

75

hepatic clearance (CLint), to predict TK, plasma concentrations and equivalent doses. While these models

76

have made enormous strides in translating in vitro assay data to human relevance, the analyses are

77

limited to 1)495 chemicals with human in vitro fup and CLint data, 2)a steady-state concentration vs. a

78

dynamic peak plasma concentration (Cmax) approach, 3)HTS without consideration of assay response

79

efficacies or quality of HTS concentration-response data, and, most importantly, 4)methods

80

inadequately evaluating in vitro responses with respect to clinical therapeutic outcomes to estimate the

81

likelihood of potential human interactions with Tox21 compounds.

82 83

Pharmaceutical researchers have addressed these types of challenges using predictive in vitro models to

84

forecast chemical-induced clinical effects. For example, the FDA has provided draft guidance documents

85

to predict drug interaction potential including the likelihood of interaction with drug metabolizing

86

enzymes and transporters in vivo.16 The only types of “interactions” considered here are chemical-

87

biological target interactions. This guidance describes calculating the ratio of peak plasma

88

concentrations (Cmax) of the chemical, at the exposure level of interest, divided by observed in vitro

89

inhibition constant (Ki) reflective of the half-maximal in vitro activity. In this approach, a Cmax/Ki ratio ≥1

ACS Paragon Plus Environment

Page 4 of 32

Page 5 of 32

Environmental Science & Technology

90

(plasma concentrations equivalent or higher than in vitro half-maximal applied concentrations) indicates

91

a ‘likely’ in vivo interaction. ‘Remote’ possibility exists if the ratio is